ReproTech has made a growth investment in Matcher Technologies to support expansion across the fertility sector, combining cryostorage expertise with electronic witnessing technology. The cryostorage provider aims to create a comprehensive platform for digitally documenting the entire IVF process while providing storage solutions.
Matcher Technologies, founded in 2005, developed IMT Matcher, described as the world’s first electronic witnessing system for fertility treatments. The UK-based company has built a global presence in fertility technology with its witnessing and traceability system used by clinics worldwide to reduce error risks in IVF procedures.
“We are thrilled to partner with Matcher to continue our combined journey of providing the highest quality, safest and most compliant products for our clinic partners,” said Brad Senstra, ReproTech CEO. “Their team, technology, mission and values align perfectly with our commitment to exceptional service, advanced technologies, and stringent compliance standards.”
The investment strengthens ReproTech’s position in reproductive cryostorage by enhancing existing traceability solutions. ReproTech, with 35 years of experience, provides storage services for sperm, oocytes, embryos, stem cells, and reproductive tissues to fertility clinics, hospital systems, and donor banks across North America.
Electronic witnessing systems have become increasingly important in fertility treatments as clinics seek to minimize human error and ensure proper tracking of genetic material throughout the IVF process. These systems typically verify that the correct samples are being used at each step of treatment, from retrieval through transfer.
“ReproTech’s reputation as a trusted storage solutions partner—with 35 years of experience—and their dedication to advancing traceability in fertility care make them an ideal partner,” said George Heywood, CEO of Matcher Technologies. “Together, we can drive innovation and enhance our service offerings in both domestic and international markets.”
Following the investment, Matcher’s operations will continue from its UK headquarters without interruption for existing users and the distributor network. Financial terms of the investment were not disclosed.
